Press release

Biophytis AGM meeting will take place on May 11, 2020 without the physical presence of its shareholders

Preparatory & all required documents for shareholders' votes are available on Biophytis website

Paris (France), Cambridge (Etats-Unis), April 30 , 2020, 7:00 p.m. CEST – BIOPHYTIS (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company specialized in the development of drug candidates for treatment of aged related diseases, especially neuromuscular diseases, will hold its Annual General Meeting (AGM) on May 11th 2020 at 2 p.m. at the offices of Reed Smith LLP, 112 avenue Kléber, 75016 Paris. As a result of restrictions placed on the movement and gatherings of persons due to the COVID-19 pandemic, the Company's Combined General Meeting will be held behind closed doors without the physical presence of its shareholders, in accordance with the provisions of Article 4 of Order no. 2020-321 of March 25th, 2020.

The notice of meeting, comprising the agenda and the draft resolutions was published in the French official legal bulletin *Bulletin des Annonces Légales Obligatoires* (BALO) n° 42. These notices include information on how to attend and vote at the General Meeting, as well as the vote bulletin. All these documents are also available on its website.

Shareholders are strongly encouraged to vote in advance of the shareholder meeting by mail, by appointing the Chairman of the meeting as your proxy or via the secure online platform VOTEACCESS.

On account of the possible effect of the Covid-19 pandemic on postal delivery times, it is recommended to return your voting forms as soon as practicable.
Please note that the voting forms should be submitted no later than :

- For postal votes, the statutory deadlines apply :
  - May 7 (4-day deadline before the Meeting) for issuing instructions to the proxy holder
  - May 8 (3-day deadline before the Meeting) for appointing the proxy
- VOTEACCESS :
  - May 10 at 3 p.m. CEST

***

About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company specialized in the development of drug candidates to slow down degenerative processes and improve functional abilities in patients with age-related diseases, especially neuromuscular diseases.

Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, currently in clinical Phase 2b in sarcopenia (SARA-INT) in the United States and Europe. A pediatric formulation of

BIO101 is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company plans to start the clinical development in H2 2020.

Sarconeos (BIO101) will also be developed as a treatment for Covid-19 (Coronavirus) for which the company has filed a clinical trial application with the French Regulatory Authority (ANSM).

The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares are listed on the Euronext Growth Paris market (Ticker: ALBPS -ISIN: FR0012816825). For more information www.biophytis.com.

Disclaimer

This press release contains forward-looking statements. While the Company considers its projections to be based on reasonable assumptions, these forward-looking statements may be called into question by a number of hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements. For a description of the risks and uncertainties likely to affect the results, BIOPHYTIS' financial position, performance or achievements and thus cause a change from the forward-looking statements, please refer to the "Risk Factors" section of the Company's 2018 Annual Report available on BIOPHYTIS website (www.biophytis.com).

This press release, and the information contained in it, does not constitute an offer to sell or subscribe, nor the solicitation of a purchase or subscription order, of BIOPHYTIS shares in any country. The elements contained in this communication may contain forward-looking information involving risks and uncertainties. The Company's actual achievements may differ materially from those anticipated in this information due to different risk and uncertainty factors. This press release was written in French and English; If there is a difference between the texts, the French version will prevail.

Biophytis Contact for Investor Relations
Evelyne Nguyen, CFO
evelyne.nguyen@biophytis.com

Media contact
Citigate Dewe Rogerson
Sylvie Berrebi/ Nathaniel Dahan/ David Dible / Quentin Dussart
biophytis@citigatedewerogerson.com
Tel: +44 (0) 20 7638 9571 / +33 (0)6 59 42 29 35